Peak bone mass in young HIV-infected patients compared with healthy controls

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 2, 2014, Pages 207-212

  Negredo, Eugènia ^a   Domingo, Pere ^b   Ferrer, Elena ^c   Estrada, Vicente ^d   Curran, Adrià ^e   Navarro, Antonio ^c   Isernia, Valentina ^d   Rosales, Joaquim ^f   Pérez Álvarez, Núria ^a,g   Puig, Jordi ^a   Bonjoch, Anna ^a   Echeverría, Patricia ^a   Podzamczer, Daniel ^c   Clotet, Bonaventura ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Sant Pau University Hospital   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f CETIR   (Spain)

^g UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

Author keywords

Antiretroviral therapy; Bone mineral density; HIV infection; Osteoporosis; Peak bone mass

Indexed keywords

ABSORPTIOMETRY, PHOTON; ADULT; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; CASE-CONTROL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; OSTEOPOROSIS; RISK FACTORS; SPAIN; YOUNG ADULT;

EID: 84893742260     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/01.qai.0000435598.20104.d6     Document Type: Article

References (40)

1. Bonjour JP, Theintz G, Law F, et al. Peak bone mass. Osteoporos Int. 1994;4(suppl 1):7-13.
2. Ferrari S, Bianchi ML, Eisman JA, et al. Osteoporosis in young adults: pathophysiology, diagnosis, and management. Osteoporos Int. 2012;23: 2735-2748.
3. Rubin K, Schirduan V, Gendreau P, et al. Predictors of axial and peripheral bone mineral density in healthy children and adolescents, with special attention to the role of puberty. J Pediatr. 1993;123:863-870.
4. Christian JC, Yu PL, Slemenda CW, et al. Heritability of bone mass: a longitudinal study in aging male twins. Am J Hum Genet. 1989;44: 429-433.
5. del Rio L, Carrascosa A, Pons F, et al. Bone mineral density of the lumbar spine in white Mediterranean Spanish children and adolescents: changes related to age, sex, and puberty. Pediatr Res. 1994;35:362-366.
6. Krall EA, Dawson-Hughes B. Heritable and life-style determinants of bone mineral density. J Bone Miner Res. 1993;8:1-9.
7. Seeman E, Hopper JL, Bach LA, et al. Reduced bone mass in daughters of women with osteoporosis. N Engl J Med. 1989;320:554-558.
8. Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825-831.
9. Bonjoch A, Figueras M, Estany C, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010;24:2827-2833.
10. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51:554-561.
11. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20: 2165-2174.
12. Knobel H, Guelar A, Vallecillo G, et al. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS. 2001;15:807-808.
13. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006;42:108-114.
14. Pollock E, Klotsas AE, Compston J, et al. Bone health in HIV infection. Br Med Bull. 2009;92:123-133.
15. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003; 278:48251-48258.
16. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol. 2005;150:67-78.
17. Wei S, Kitaura H, Zhou P, et al. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest. 2005;115:282-290.
18. Guerri-Fernandez R, Vestergaard P, Carbonell C, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender and co-morbidities: a population-based cohort study. J Bone Miner Res. 2013;28:1259-1263.
19. Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93: 3499-3504.
20. Womack JA, Goulet JL, Gibert C, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6:e17217.
21. Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011; 52:1061-1068.
22. Bonnick S. Bone density data. In: Bone Densitometry in Clinical Practice. Application and Interpretation. 2nd ed. New York, NY: Humana Press; 2004:111-126.
23. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy safety tenofovir DF vs stavudine combination therapy antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
24. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519-1529.
25. Hansen AB, Obel N, Nielsen H, et al. Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitorsparing highly active antiretroviral therapy: data from a randomized trial. HIV Med. 2011;12:157-165.
26. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937-946.
27. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-972.
28. Bolland MJ, Grey AB, Horne AM, et al. Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf). 2006;65:191-197.
29. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91:2938-2945.
30. Yin MT, Kendall MA, Wu X, et al. Fractures after antiretroviral initiation. AIDS. 2012;26:2175-2184.
31. da Fonseca MA. Osteoporosis: an increasing concern in pediatric dentistry. Pediatr Dent. 2011;33:241-245.
32. Mesias M, Seiquer I, Navarro MP. Calcium nutrition in adolescence. Crit Rev Food Sci Nutr. 2011;51:195-209.
33. Roef G, Lapauw B, Goemaere S, et al. Thyroid hormone status within the physiological range affects bone mass and density in healthy men at the age of peak bone mass. Eur J Endocrinol. 2011;164:1027-1034.
34. Shivane VK, Sarathi V, Lila AR, et al. Peak bone mineral density and its determinants in an Asian Indian population. J Clin Densitom. 2012;15: 152-158.
35. Massanella M, Negredo E, Perez-Alvarez N, et al. CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART. AIDS. 2010;24:959-968.
36. Hinriksdottir G, Arngrimsson SA, Misic MM, et al. Lean soft tissue contributes more to bone health than fat mass independent of physical activity in women across the lifespan. Maturitas. 2013. pii: S0378-5122 (12)00409-4.
37. Park JH, Song YM, Sung J, et al. The association between fat and lean mass and bone mineral density: the Healthy Twin Study. Bone. 2012;50: 1006-1011.
38. Sharma A, Tian F, Yin MT, et al. Association of regional body composition with bone mineral density in HIV-infected and HIV-uninfected women: women's interagency HIV study. J Acquir Immune Defic Syndr. 2012;61:469-476.
39. Waters DL, Vawter R, Qualls C, et al. Long-term maintenance of weight loss after lifestyle intervention in frail, obese older adults. J Nutr Health Aging. 2013;17:3-7.
40. Nguyen TV, Howard GM, Kelly PJ, et al. Bone mass, lean mass, and fat mass: same genes or same environments? Am J Epidemiol. 1998;147:3-16.